
|Articles|April 1, 2004
Angiogenesis plays role in ophthalmic diseases
Editor's Note: Due to the large volume of information presented at the Angiogenesis 2004 meeting, this article is an overview of many of the presentations. Ophthalmology Times will provide greater detail of many of the sessions in upcoming issues.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves Amneal Pharmaceuticals' cyclosporine ophthalmic emulsion 0.05%
2
Avisi Technologies treats first patient in SAPPHIRE trial for glaucoma
3
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
4
Belite Bio releases topline results from phase 3 DRAGON trial of Tinlarebant for STGD1
5















































.png)


